



DECLE27.001APC

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Vannuffel et al.) Group Art Unit 1634
Appl. No. : 09/509,234) I hereby certify that this correspondence
Filed : September 25, 2000) and all marked attachments are being
For : GENETIC SEQUENCES,) deposited with the United States Postal
DIAGNOSTIC AND/OR) Service as first-class mail in an envelope
QUANTIFICATION) addressed to: United States Patent and
METHODS AND DEVICES) Trademark Office, P.O. Box 2327,
FOR THE IDENTIFICATION) Arlington, VA 22202, on
OF STAPHYLOCOCCI)
STRAINS)
Examiner : C. J. Myers)

January 3, 2003
(Date)
Catherine M. Sanders
Catherine M. Sanders, Reg. No. 50,660

RECEIVED

AMENDMENT AND RESPONSE TO OFFICE ACTION MAILED JULY 3, 2002

JAN 09 2003

United States Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

TECH CENTER 1600/2900

Dear Sir:

In response to the Office Action mailed July 3, 2002 (Paper # 19), please amend the above-captioned patent application as follows:

IN THE SPECIFICATION:

Please amend the paragraph beginning on page 8, line 16 as follows:

Preferably, the oligonucleotide according to the invention is selected from the group consisting of the following nucleotide sequences:

- ANAATGAANTTTACNAATTTNACNGCNANAGANTT (SEQ ID NO: 2) and more particularly *femS1* TAATGAAGTTTACAAAATTT (SEQ ID NO: 3) or *femS2* TAATGAAGTTTACNAAATTT (SEQ ID NO: 4)
- ATGNCNNANAGNCATTTNACNCANA (SEQ ID NO: 5) and more particularly *femU1* ("universal" sequence sense of the multiplex PCR): TGCCATATAGTCATTTACGC (SEQ ID NO: 6)
- TAGTNGGNATNAANAANAANNATAANGANGTNATTGC (SEQ ID NO: 7)